Venlafaxine Hcl
Rank #214 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$64.7M
Total Cost
2,187,710
Total Claims
$64.7M
Total Cost
66,093
Prescribers
$30
Cost per Claim
187,605
Beneficiaries
4,026,256
30-Day Fills
$979
Avg Cost/Provider
33
Avg Claims/Provider
Share of Medicare Part D Spending
0.02%
of total Medicare Part D spending
$64.7M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $64.7M total
Top Prescribers of Venlafaxine Hcl
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Lewis Lane | Psychiatry & Neurology | Dana Point, CA | 19 | $50K |
| 2 | Karen Hedden | Nurse Practitioner | Sandy, OR | 21 | $41K |
| 3 | Simon Mcclure | Psychiatry | Bridgeport, WV | 1,315 | $36K |
| 4 | Ryan Grandgenett | Family Practice | Ames, IA | 13 | $34K |
| 5 | Thomas Shoaf | Psychiatry | Richardson, TX | 11 | $34K |
| 6 | Kimberly Cress | Psychiatry | Sugar Land, TX | 12 | $31K |
| 7 | Samuel Greenstein | Psychiatry | Cincinnati, OH | 44 | $31K |
| 8 | Iuri Cernev | Nurse Practitioner | Salem, OR | 21 | $30K |
| 9 | Theresa Bell | Psychiatry | Galloway, NJ | 20 | $30K |
| 10 | Candice Clark | Nurse Practitioner | Chapel Hill, NC | 26 | $30K |
| 11 | Lucia San Miguel | Psychiatry & Neurology | Mayaguez, PR | 49 | $28K |
| 12 | Ira Lipton | Psychiatry & Neurology | New York, NY | 15 | $27K |
| 13 | Cristina Cusin | Psychiatry | Boston, MA | 17 | $27K |
| 14 | Robert Stout | Internal Medicine | Lagrange, GA | 14 | $27K |
| 15 | Leduar Morales Castillo | Nurse Practitioner | Miami, FL | 464 | $27K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 211 | Dabigatran Etexilate Mesylate (Dabigatran Etexilate) | $66.0M | 220,652 |
| 212 | Netarsudil Mesylate (Rhopressa) | $65.6M | 129,116 |
| 213 | Risperidone Microspheres (Risperdal Consta) | $64.8M | 47,567 |
| 214 | Venlafaxine Hcl (Venlafaxine Hcl) | $64.7M | 2,187,710 |
| 215 | Canagliflozin (Invokana) | $63.7M | 66,550 |
| 216 | Belimumab (Benlysta) | $63.4M | 13,386 |
| 217 | Collagenase Clostridium Hist. (Santyl) | $63.3M | 70,641 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology